CSE:AGN - Post Discussion
Post by
SkywalkerofLuke on Apr 05, 2023 4:04pm
AGN Completed 2nd Cohort of Phase 1 DMT Study
AGN.c recently announced they completed the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (DMT).
AGNPF is a Canadian clinical stage pharmaceutical development company and has been approved to move forward.
The CEO stated, “The sooner we can finalize the correct dose and the optimum exposure period, the faster we can move into Phase 2 studies where we can test DMT on patients that have suffered a serious brain injury.”
https://www.algernonpharmaceuticals.com/news-media/news-releases/detail/180/algernon-neuroscience-announces-successful-dosing-of-2nd
Be the first to comment on this post